Tempest Therapeutics shares surge 32.35% after-hours after completing Factor Bioscience CAR-T asset acquisition.

Tempest Therapeutics (NASDAQ: TPST) surged 32.35% in after-hours trading following the announcement of completing its all-stock acquisition of Factor Bioscience’s dual-targeting CAR-T pipeline, including TPST-2003, a clinical-stage CD-19/BCMA therapy. The transaction, approved at the company’s annual shareholder meeting, added next-generation CAR-T assets and brought Matt Angel on as CEO, signaling strategic momentum. The acquisition, executed as the micro-cap biotech traded near its 52-week low, positions Tempest to advance TPST-2003 toward a 2027 BLA filing in China and potential U.S. registration trials, while existing cash and partnership funding extend operational runway through mid-2027. The move underscores renewed focus on expanding its pipeline in oncology, with TPST-1120 (liver cancer) and TPST-1495 (familial adenomatous polyposis) also in development.